Results 31 to 40 of about 56,186 (320)

Immunolocalization of steroidogenic enzymes in the vaginal mucous of Galea spixii during the estrous cycle. [PDF]

, 2017
BackgroundThe synthesis of sex steroids is controlled by several enzymes such as17α-hydroxylase cytochrome P450 (P450c17) catalyzing androgen synthesis and aromatase cytochrome P450 (P450arom) catalyzing estrogen synthesis, both of which must complex ...
Assis Neto, Antônio Chaves de, Conley, Alan James, de Oliveira, Moacir Franco, Dos Santos, Amilton Cesar, Oliveira, Gleidson Benevides, Viana, Diego Carvalho   +5 more
core   +1 more source

Testosterone affects song modulation during simulated territorial intrusions in male black redstarts (Phoenicurus ochruros) [PDF]

, 2012
Although it has been suggested that testosterone plays an important role in resource allocation for competitive behavior, details of the interplay between testosterone, territorial aggression and signal plasticity are largely unknown.
Apfelbeck, Beate, Bartell, Paul A., Goymann, Wolfgang, Kiefer, Sarah, Kipper, Silke, Mortega, Kim G.   +5 more
core   +3 more sources

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]

, 2013
IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P, Baselga, José, Burris, Howard A, Cahana, Ayelet, Campone, Mario, Erdkamp, Frans, Feng, Wentao, Gnant, Michael, Harb, Wael A, Hortobagyi, Gabriel N, Lebwohl, David, Melichar, Bohuslav, Noguchi, Shinzaburo, Petrakova, Katarina, Piccart, Martine, Pistilli, Barbara, Pritchard, Kathleen I, Rugo, Hope S, Taran, Tetiana, Yardley, Denise A   +19 more
core   +2 more sources

Locally Advanced Breast Cancer Patient’s Recurrence Rates Comparison Received Steroidal and Nonsteroidal Aromatase Inhibitor Based on Luminal

Biomolecular and Health Science Journal
Introduction: Aromatase inhibitors are hormonal therapies used in menopausal breast cancer with positive progesterone receptors and/or estrogen receptors.
Desak Gede Agung Suprabawati, Bernadeta Hernik Setiyandari, Dwi Hari Susilo, Bara Kharisma, Rizki Amalia   +4 more
doaj   +1 more source

A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy. [PDF]

, 2019
BACKGROUND:It remains unclear how information about aromatase inhibitors (AI) impacts women's decision-making about persistence with endocrine therapy.
Green, Emily, Khakshooy, Sally, Pieters, Huibrie C, Sleven, Miriam, Stanton, Annette L   +4 more
core   +4 more sources

Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy

Oncology Reviews, 2016
This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast ...
Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh   +2 more
doaj   +1 more source

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]

, 2018
Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo, A Subramanian, AH Evans, Allan Thornhill, Alshad S. Lalani, Aradhana Rani, C Trapnell, CK Osborne, CX Ma, Eugene Schuster, FL Chen, Francesca Avogadri-Connors, G Arpino, HJ Burstein, IE Smith, J Baselga, Joanna Nikitorowicz-Buniak, KE Bachman, KE O'Reilly, L Gandhi, LA Martin, LA Martin, Lesley-Ann Martin, LV Sequist, M Arnedos, M Dowsett, Mitch Dowsett, MT Weigel, N Patani, N Simigdala, NA O'Brien, Nikiana Simigdala, R Ribas, Ricardo Ribas, Richard E. Cutler, S Johnston, SC Drury, SN Mohd Nafi, SP Newman, Stephanie K. Guest, Stephen R. Johnston, Sunil Pancholi, T Nagashima, W Luo   +43 more
core   +6 more sources

Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone

Gynecologic Oncology Reports, 2017
Introduction: Young women with endometrial intraepithelial hyperplasia or low-grade endometrial carcinoma are potential candidates for conservative fertility sparing therapy utilizing progesterone rather than hysterectomy.
Alli Straubhar, Andrew P. Soisson, Mark Dodson, Elise Simons   +3 more
doaj   +1 more source

Apoptosis and autophagy in breast cancer cells following exemestane treatment. [PDF]

PLoS ONE, 2012
Aromatase inhibitors (AIs), which block the conversion of androgens to estrogens, are used for hormone-dependent breast cancer treatment. Exemestane, a steroidal that belongs to the third-generation of AIs, is a mechanism-based inhibitor that binds ...
Cristina Amaral, Margarida Borges, Soraia Melo, Elisiário Tavares da Silva, Georgina Correia-da-Silva, Natércia Teixeira   +5 more
doaj   +1 more source

Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]

, 2015
BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T, Janku, Filip, Kurzrock, Razelle, Moulder, Stacy L, Stephens, Philip J, Wheler, Jennifer J, Yelensky, Roman   +6 more
core   +2 more sources